Evidence of efficacy of biologics in smokers with severe asthma in the SHARP CRC registry

Jeremy Charriot; Marco Caminati; Aruna Bansal; Shane Hanon; Florence Schleich; Sanja Popovic-Grle; Marina Lampalo; Celeste Porsbjerg; Arnaud Bourdin; Zsuzsanna Csoma; Dora Ludviksdottir; Giorgio Walter Canonica; Enrico Heffler; Cristina Cardini; Ineta Grisle; Kristina Bieksiene; Anneke Ten Brinke; Jacob Sont; Piotr Kuna; Maria Morawska; Florin Mihaltan; Sanja Hromis; Peter Kopac; Valentyna Yasinska; Fabienne Jaun; Sabina Skrgat; Ratko Djukanovic; Bilun Gemicioglu

doi:10.1183/13993003.congress-2025.OA2210

Evidence of efficacy of biologics in smokers with severe asthma in the SHARP CRC registry

Jeremy Charriot, Marco Caminati, Aruna Bansal, Shane Hanon, Florence Schleich, Sanja Popovic-Grle, Marina Lampalo, Celeste Porsbjerg, Arnaud Bourdin, Zsuzsanna Csoma, Dora Ludviksdottir, Giorgio Walter Canonica, Enrico Heffler, Cristina Cardini, Ineta Grisle, Kristina Bieksiene, Anneke Ten Brinke, Jacob Sont, Piotr Kuna, Maria MorawskaFlorin Mihaltan, Sanja Hromis, Peter Kopac, Valentyna Yasinska, Fabienne Jaun, Sabina Skrgat, Ratko Djukanovic, Bilun Gemicioglu

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Abstract

Background: Real-world responses to biologics were assessed by cigarette smoking exposure.

Methods: Clinical and functional data from 3,689 severe asthmatics in the ERS SHARP (Severe Heterogeneous Asthma Research-Patient Centred) registry were analyzed using the OMOP Common Data Model at baseline and after 1-year of treatment with biologics.

Results: Among 2,282 never smokers, 505 ex-smokers (<10 pack-years [py]), 766 (≥10 py), and 136 current smokers, respectively, symptom control (ACT≥20/ACQ≤1.5) improved (+220%, +215%, +200%), frequent exacerbations (>2/year) decreased (-67%, -65%, -61%), AQLQ improved (+18%, +23%, +118%), and FEV1 pre-BD (%pred) increased (+10%, +9%, +6%) with no significant differences vs. never smokers, except for AQLQ for which current smokers experienced greatest improvement (Table 1). Survey of physicians showed that 25% oppose prescription of biologics to current smokers and >50% were dissatisfied with current treatment guidelines.

Conclusion: Former/current smokers respond as well as never smokers to biologics, with AQLQ improving most in current smokers. Management disparities identified across Europe need for inclusive, evidence-based guidelines.

Originalsprog	Engelsk
Artikelnummer	OA2210
Bogserie	European Respiratory Journal. Supplement
Vol/bind	66
Udgave nummer	suppl 69
ISSN	0904-1850
DOI	https://doi.org/10.1183/13993003.congress-2025.OA2210
Status	Udgivet - 2025

Adgang til dokumentet

10.1183/13993003.congress-2025.OA2210

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Charriot, J., Caminati, M., Bansal, A., Hanon, S., Schleich, F., Popovic-Grle, S., Lampalo, M., Porsbjerg, C., Bourdin, A., Csoma, Z., Ludviksdottir, D., Canonica, G. W., Heffler, E., Cardini, C., Grisle, I., Bieksiene, K., Ten Brinke, A., Sont, J., Kuna, P., ... Gemicioglu, B. (2025). Evidence of efficacy of biologics in smokers with severe asthma in the SHARP CRC registry. European Respiratory Journal. Supplement, 66( suppl 69), Artikel OA2210. https://doi.org/10.1183/13993003.congress-2025.OA2210

Charriot, J, Caminati, M, Bansal, A, Hanon, S, Schleich, F, Popovic-Grle, S, Lampalo, M, Porsbjerg, C, Bourdin, A, Csoma, Z, Ludviksdottir, D, Canonica, GW, Heffler, E, Cardini, C, Grisle, I, Bieksiene, K, Ten Brinke, A, Sont, J, Kuna, P, Morawska, M, Mihaltan, F, Hromis, S, Kopac, P, Yasinska, V, Jaun, F, Skrgat, S, Djukanovic, R & Gemicioglu, B 2025, 'Evidence of efficacy of biologics in smokers with severe asthma in the SHARP CRC registry', European Respiratory Journal. Supplement, bind 66, nr. suppl 69, OA2210. https://doi.org/10.1183/13993003.congress-2025.OA2210

@article{4ec57c76f52a4ea9af5e80f7a9ff5bbc,

title = "Evidence of efficacy of biologics in smokers with severe asthma in the SHARP CRC registry",

abstract = "Background: Real-world responses to biologics were assessed by cigarette smoking exposure.Methods: Clinical and functional data from 3,689 severe asthmatics in the ERS SHARP (Severe Heterogeneous Asthma Research-Patient Centred) registry were analyzed using the OMOP Common Data Model at baseline and after 1-year of treatment with biologics.Results: Among 2,282 never smokers, 505 ex-smokers (<10 pack-years [py]), 766 (≥10 py), and 136 current smokers, respectively, symptom control (ACT≥20/ACQ≤1.5) improved (+220%, +215%, +200%), frequent exacerbations (>2/year) decreased (-67%, -65%, -61%), AQLQ improved (+18%, +23%, +118%), and FEV1 pre-BD (%pred) increased (+10%, +9%, +6%) with no significant differences vs. never smokers, except for AQLQ for which current smokers experienced greatest improvement (Table 1). Survey of physicians showed that 25% oppose prescription of biologics to current smokers and >50% were dissatisfied with current treatment guidelines.Conclusion: Former/current smokers respond as well as never smokers to biologics, with AQLQ improving most in current smokers. Management disparities identified across Europe need for inclusive, evidence-based guidelines.",

author = "Jeremy Charriot and Marco Caminati and Aruna Bansal and Shane Hanon and Florence Schleich and Sanja Popovic-Grle and Marina Lampalo and Celeste Porsbjerg and Arnaud Bourdin and Zsuzsanna Csoma and Dora Ludviksdottir and Canonica, {Giorgio Walter} and Enrico Heffler and Cristina Cardini and Ineta Grisle and Kristina Bieksiene and {Ten Brinke}, Anneke and Jacob Sont and Piotr Kuna and Maria Morawska and Florin Mihaltan and Sanja Hromis and Peter Kopac and Valentyna Yasinska and Fabienne Jaun and Sabina Skrgat and Ratko Djukanovic and Bilun Gemicioglu",

year = "2025",

doi = "10.1183/13993003.congress-2025.OA2210",

language = "English",

volume = "66",

journal = "European Respiratory Journal. Supplement",

issn = "0904-1850",

publisher = "European Respiratory Society",

number = " suppl 69",

}

TY - ABST

T1 - Evidence of efficacy of biologics in smokers with severe asthma in the SHARP CRC registry

AU - Charriot, Jeremy

AU - Caminati, Marco

AU - Bansal, Aruna

AU - Hanon, Shane

AU - Schleich, Florence

AU - Popovic-Grle, Sanja

AU - Lampalo, Marina

AU - Porsbjerg, Celeste

AU - Bourdin, Arnaud

AU - Csoma, Zsuzsanna

AU - Ludviksdottir, Dora

AU - Canonica, Giorgio Walter

AU - Heffler, Enrico

AU - Cardini, Cristina

AU - Grisle, Ineta

AU - Bieksiene, Kristina

AU - Ten Brinke, Anneke

AU - Sont, Jacob

AU - Kuna, Piotr

AU - Morawska, Maria

AU - Mihaltan, Florin

AU - Hromis, Sanja

AU - Kopac, Peter

AU - Yasinska, Valentyna

AU - Jaun, Fabienne

AU - Skrgat, Sabina

AU - Djukanovic, Ratko

AU - Gemicioglu, Bilun

PY - 2025

Y1 - 2025

N2 - Background: Real-world responses to biologics were assessed by cigarette smoking exposure.Methods: Clinical and functional data from 3,689 severe asthmatics in the ERS SHARP (Severe Heterogeneous Asthma Research-Patient Centred) registry were analyzed using the OMOP Common Data Model at baseline and after 1-year of treatment with biologics.Results: Among 2,282 never smokers, 505 ex-smokers (<10 pack-years [py]), 766 (≥10 py), and 136 current smokers, respectively, symptom control (ACT≥20/ACQ≤1.5) improved (+220%, +215%, +200%), frequent exacerbations (>2/year) decreased (-67%, -65%, -61%), AQLQ improved (+18%, +23%, +118%), and FEV1 pre-BD (%pred) increased (+10%, +9%, +6%) with no significant differences vs. never smokers, except for AQLQ for which current smokers experienced greatest improvement (Table 1). Survey of physicians showed that 25% oppose prescription of biologics to current smokers and >50% were dissatisfied with current treatment guidelines.Conclusion: Former/current smokers respond as well as never smokers to biologics, with AQLQ improving most in current smokers. Management disparities identified across Europe need for inclusive, evidence-based guidelines.

AB - Background: Real-world responses to biologics were assessed by cigarette smoking exposure.Methods: Clinical and functional data from 3,689 severe asthmatics in the ERS SHARP (Severe Heterogeneous Asthma Research-Patient Centred) registry were analyzed using the OMOP Common Data Model at baseline and after 1-year of treatment with biologics.Results: Among 2,282 never smokers, 505 ex-smokers (<10 pack-years [py]), 766 (≥10 py), and 136 current smokers, respectively, symptom control (ACT≥20/ACQ≤1.5) improved (+220%, +215%, +200%), frequent exacerbations (>2/year) decreased (-67%, -65%, -61%), AQLQ improved (+18%, +23%, +118%), and FEV1 pre-BD (%pred) increased (+10%, +9%, +6%) with no significant differences vs. never smokers, except for AQLQ for which current smokers experienced greatest improvement (Table 1). Survey of physicians showed that 25% oppose prescription of biologics to current smokers and >50% were dissatisfied with current treatment guidelines.Conclusion: Former/current smokers respond as well as never smokers to biologics, with AQLQ improving most in current smokers. Management disparities identified across Europe need for inclusive, evidence-based guidelines.

U2 - 10.1183/13993003.congress-2025.OA2210

DO - 10.1183/13993003.congress-2025.OA2210

M3 - Conference abstract in journal

SN - 0904-1850

VL - 66

JO - European Respiratory Journal. Supplement

JF - European Respiratory Journal. Supplement

IS - suppl 69

M1 - OA2210

ER -